ADC Therapeutics S.A.
NYSE ADCT · Epalinges, Switzerland
Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
ADC Therapeutics S.A. is a clinical trial sponsor based in Epalinges, Switzerland, listed as NYSE ADCT. It has 2 active clinical trials with 594 planned participants, across 11 therapeutic areas. Since 2021 it has completed 5 trials and stopped 11 early.
Trial track record · since 2021
Financials · NYSE ADCT
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about ADC Therapeutics S.A
ADC Therapeutics S.A is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 594 planned participants, in Cardiovascular, Dermatology, GI & liver, Hematology and other areas. Since 2021 it has completed 5 trials and stopped 11 early.
ADC Therapeutics S.A is based in Epalinges, Switzerland and is listed as NYSE ADCT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with ADC Therapeutics S.A; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-07-20.
Approve Suite is not affiliated with ADC Therapeutics S.A..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.